<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280149</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IND 4458</org_study_id>
    <nct_id>NCT01280149</nct_id>
  </id_info>
  <brief_title>Reduction of IgE Antibody in Human Allergic Subjects</brief_title>
  <official_title>Reduction of IgE Antibody in Human Allergic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a neuropeptide, substance P, when injected
      along with an allergen, such as ragweed, can reduce allergic reactivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic Rhinitis (Hay fever) affects many children and adults and is a risk factor for
      development of asthma. This study utilizes the neurotransmitter, substance P, a small
      molecule which is present in nerve endings, the brain, skin, lungs and the gastrointestinal
      tract. Subjects will receive substance P and a low dosage of an allergen, such as ragweed in
      an attempt to reduce allergic reactivity.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CBER ID50 skin test result</measure>
    <time_frame>1 to 6 months after completing injections</time_frame>
    <description>The ID50 skin test result utilizes FDA CBER methodology to determine the change in allergic skin reactivity to ragweed and grass pollen allergens.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>substance P-low dose allergen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substance P injections with 8 sequential, increasing doses of allergen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>substance P-moderate dose allergen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substance P with sequential, increasing doses of allergen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>substance P-low/moderate dose allergen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>substance P with 16 sequential increasing doses of allergen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>substance P-placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo injections of substance P and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo-low dose allergen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo injections with 8 sequential increasing low dose allergen injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>substance P placebo and allergen placebo (weekly)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>substance P</intervention_name>
    <description>injections of substance P and low dose allergen or placebo</description>
    <arm_group_label>substance P-low dose allergen</arm_group_label>
    <arm_group_label>substance P-moderate dose allergen</arm_group_label>
    <arm_group_label>substance P-low/moderate dose allergen</arm_group_label>
    <arm_group_label>substance P-placebo</arm_group_label>
    <arm_group_label>placebo-low dose allergen</arm_group_label>
    <arm_group_label>placebo-placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>substance P injections</intervention_name>
    <description>injections of substance P for 8 weeks</description>
    <arm_group_label>substance P-low dose allergen</arm_group_label>
    <arm_group_label>substance P-moderate dose allergen</arm_group_label>
    <arm_group_label>substance P-low/moderate dose allergen</arm_group_label>
    <arm_group_label>substance P-placebo</arm_group_label>
    <arm_group_label>placebo-low dose allergen</arm_group_label>
    <arm_group_label>placebo-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  positive immediate type skin test to ragweed or grass pollen or a third (standardized)
             allergen if both ragweed and grass pollen allergen are not positive

          -  volunteers should be available for allergen injections and then cutaneous titrations
             for approximately 1 year from the start of the enrollment period

        Exclusion Criteria:

          -  volunteer is pregnant or lactating

          -  abnormal electrocardiogram for subjects over 50 years of age

          -  use of beta adrenergic antagonists or tricyclic antidepressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A Greenberger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Paul Greenberger</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>substance P</keyword>
  <keyword>allergic rhinitis</keyword>
  <keyword>allergen immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Substance P</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

